HomeCompareAULT vs ABBV

AULT vs ABBV: Dividend Comparison 2026

AULT yields 930.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AULT wins by $1.19M in total portfolio value
10 years
AULT
AULT
● Live price
930.67%
Share price
$0.21
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.29M
Annual income
$5,923.25
Full AULT calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AULT vs ABBV

📍 AULT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAULTABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AULT + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AULT pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AULT
Annual income on $10K today (after 15% tax)
$79,106.56/yr
After 10yr DRIP, annual income (after tax)
$5,034.76/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $16,021.24/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AULT + ABBV for your $10,000?

AULT: 50%ABBV: 50%
100% ABBV50/50100% AULT
Portfolio after 10yr
$695.2K
Annual income
$15,347.50/yr
Blended yield
2.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AULT
No analyst data
Altman Z
-0.7
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AULT buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAULTABBV
Forward yield930.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$1.29M$102.3K
Annual income after 10y$5,923.25$24,771.77
Total dividends collected$841.1K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AULT vs ABBV ($10,000, DRIP)

YearAULT PortfolioAULT Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$57,233$46,533.27$11,550$430.00+$45.7KAULT
2$185,691$124,451.00$13,472$627.96+$172.2KAULT
3$387,369$188,680.04$15,906$926.08+$371.5KAULT
4$598,412$183,927.68$19,071$1,382.55+$579.3KAULT
5$773,074$132,772.81$23,302$2,095.81+$749.8KAULT
6$907,342$80,152.28$29,150$3,237.93+$878.2KAULT
7$1,014,815$43,959.40$37,536$5,121.41+$977.3KAULT
8$1,108,827$22,974.92$50,079$8,338.38+$1.06MAULT
9$1,198,175$11,730.52$69,753$14,065.80+$1.13MAULT
10$1,287,971$5,923.25$102,337$24,771.77+$1.19MAULT

AULT vs ABBV: Complete Analysis 2026

AULTStock

Ault Alliance, Inc., through its subsidiaries, provides customized solutions for the military markets in North America, Europe, the Middle East, and internationally. The company operates through eight segments: Energy and Infrastructure, Technology and Finance, SMC, BNI, GIGA, TurnOnGreen, AGREE, and Ault Disruptive. It offers lifting services; virtual markets, real world goods marketplaces, gaming, sweepstakes gaming, contest of skill, and building private spaces, as well as social hubs and unique and virtual world. The company also provides consumer electronic solutions; commercial loans, convertible notes, and revolving lines of credit; and virtual training courses through the LightSpeedVT platform, as well as creates various media, communications, and content, including web development, corporate communications, social media, and scripted and unscripted television. In addition, it invests in public and private companies; and various commercial and residential real estate, including hospitality, multifamily, and industrial properties, as well as operates hotels and other commercial real estate, and data centers; and Bitcoin mining activities. It sells its products directly through its sales force, as well as through manufacturer representatives and distributors. It serves crane services, oil exploration, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles industries. The company was formerly known as BitNile Holdings, Inc. and changed its name to Ault Alliance, Inc. in January 2023. Ault Alliance, Inc. was incorporated in 1969 and is headquartered in Las Vegas, Nevada.

Full AULT Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AULT vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AULT vs SCHDAULT vs JEPIAULT vs OAULT vs KOAULT vs MAINAULT vs JNJAULT vs MRKAULT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.